Generic firms might be able to purchase branded drugs for bioequivalence studies from Europe under concepts that FDA is considering. Commissioner Gottlieb says FDA may allow generic firms to seek wavier of shared REMS to avoid protracted negotiations. 

Sponsors contend that changes to bioequivalence guidances in the middle of a review cycle have delayed approvals; FDA says rule changes might be difficult because of existing regulations.

Agency eager to hear suggestions on the subject, also known as product hopping, but even reform advocates were cautious of stifling meaningful reformulations of products.